EPO upholds patent on Copaxone 40mg

1 April 2019

A three-member panel of the European Patent Office’s (EPO) Opposition Division upheld patent EP 2,949,335 covering Copaxone (glatiramer acetate) 40mg in Europe.

Copaxone is Israel-based Teva Pharmaceutical Industries’ (NYSE: TEVA) best-selling treatment for multiple sclerosis, and generated 2018 sales of $2.4 billion, but, as a result of continued generic erosion, sales of ~$1.5 billion are expected in 2019.

The Opposition Division will issue its written underlying rationale on the decision within a few months, according to the company, whose shares edged up 1.16% by early afternoon trading on the domestic market.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK